Chronic Bacterial Prostatitis Clinical Trial
Official title:
Chronic Bacterial Prostatitis: Efficacy of Short-lasting Antibiotic Therapy With Prulifloxacin (Unidrox®) in Association With Saw Palmetto Extract, Lactobacillus Sporogens and Arbutin (Lactorepens®)
Background - bacterial prostatitis (BP) is a common condition accounting responsible for
about 5-10% of all prostatitis cases; chronic bacterial prostatitis (CBP) classified as type
II, are less common but is a condition that significantly hampers the quality of life, (QoL)
because not only is it a physical condition but also a psychological distress. Commonly
patients are treated with antibiotics alone, and in particular fluoroquinolones are
suggested by the European Urology guidelines. This approach, although recommended, may not
be enough. Thus, a multimodal approach to the prolonged antibiotic therapy may be helpful.
Methods - 210 patients affected by chronic bacterial prostatitis were enrolled in the study.
All patients were positive to Meares-Stamey test and symptoms duration was > 3 months. The
purpose of the study was to evaluate the efficacy of a long lasting therapy with a
fluoroquinolone in association with a nutraceutical supplement (prulifloxacin 600 mg for 21
days and an association of Serenoa repens 320 mg, Lactobacillus Sporogens 200 mg, Arbutin
100 mg for 30 days). Patients were randomized in two groups (A and B) receiving respectively
antibiotic alone and an association of antibiotic plus supplement.
n/a
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00672087 -
Diagnostic Challenges in IC (and Male CPPS)
|
||
| Completed |
NCT03201796 -
Prulifloxacin in Chronic Bacterial Prostatitis (CBP)
|
Phase 2 |